Alzinova AB (publ)

Stockholm Stock Exchange ALZ.ST

Alzinova AB (publ) Net Income for the year ending December 31, 2023: USD -1.63 M

Alzinova AB (publ) Net Income is USD -1.63 M for the year ending December 31, 2023, a -30.32% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Alzinova AB (publ) Net Income for the year ending December 31, 2022 was USD -1.25 M, a -49.47% change year over year.
Alzinova AB (publ) Net Income for the year ending December 31, 2021 was USD -835.07 K, a -5.99% change year over year.
Alzinova AB (publ) Net Income for the year ending December 31, 2020 was USD -787.86 K, a -19.39% change year over year.
Alzinova AB (publ) Net Income for the year ending December 31, 2019 was USD -659.93 K, a -40.02% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Stockholm Stock Exchange: ALZ.ST

Alzinova AB (publ)

CEO	Dr. Tord Labuda M.Sc., Ph.D.
IPO Date	Nov. 25, 2015
Location	Sweden
Headquarters	Pepparedsleden 1
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Key trends

Past 5 years